Platelet-rich plasma: support for its use in wound healing.

Abstract

Previous topical growth factor studies have shown that recombinant human platelet-derived growth factor-BB isomer (rhPDGF-BB) is an efficacious treatment of chronic diabetic foot ulceration. A newer treatment, autologous platelet-rich plasma (PRP), represents a greater similarity to the natural healing process as a composite of multiple growth factors, is safe due to its autologous nature, and is produced as needed from patient blood. A review of the literature shows few studies performed with scientific rigor, although the safety of PRP appears to be validated. As the use of PRP increases, additional studies may establish PRP as an efficacious treatment modality and guide future treatment of chronic diabetic foot ulceration.

• Authors: Kathleen M Lacci, Alan Dardik
• Journal: The Yale journal of biology and medicine (Yale J Biol Med) Vol. 83 Issue 1 Pg. 1-9 (Mar 2010) ISSN: 1551-4056 [Electronic] United States
• PMID: 20351977 (Publication Type: Journal Article, Review)

Chemical References

• Platelet-Derived Growth Factor
• Proto-Oncogene Proteins c-sis
• Becaplermin

Topics

• Becaplermin
• Blood Transfusion, Autologous
• Clinical Trials as Topic
• Diabetic Foot (drug therapy)
• Humans
• Platelet-Derived Growth Factor (therapeutic use)
• Platelet-Rich Plasma (metabolism)
• Proto-Oncogene Proteins c-sis
• Wound Healing